FDA Approves Beech Tree Labs' Recurrent Oral Herpes Infections IND Application - Another Successful Collaboration Milestone for NCRA and BTL
Beech Tree Labs has announced that the FDA has approved its IND for a Phase 1/2a clinical evaluation of BTL-TML-HSV, a novel therapeutic agent for treating recurrent oral herpes infections....
Investigator Responsibilities Revisited by FDA
By Glenda Guest, vice president, Norwich Clinical Research Associates (NCRA) While the title of the new guidance from FDA is 'Investigator Responsibilities', in reality sponsors also...
FDA Approves Beech Tree Labs' Influenza IND Application
Beech Tree Labs, Inc., has announced that the FDA has approved its IND for a 180 patient Phase 1/2a clinical evaluation of BTL-TML001, a novel therapeutic agent for treating acute influenza...